A
SPRY icon

AlphaQuest’s ARS Pharmaceuticals SPRY Stock Holding History

AlphaQuest’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-32,970
Closed -$384K – 1801
2025
Q4 		$384K Sell
32,970
-12,849
-28% -$125K 0.02% 1021
2025
Q3 		$460K Buy
45,819
+22,283
+95% +$320K 0.03% 844
2025
Q2 		$411K Buy
23,536
+5,472
+30% +$79K 0.04% 709
2025
Q1 		$227K Buy
18,064
+15,953
+756% +$192K 0.02% 924
2024
Q4 		$22.3K Buy
+2,111
New +$29.6K ﹤0.01% 1411

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

AlphaQuest's SPRY Position: Q1 2026 in Review

AlphaQuest sold out of ARS Pharmaceuticals (SPRY) in Q1 2026, closing a stake of 32,970 shares — an estimated $384K sold.

AlphaQuest first reported a position in SPRY in Q4 2024 and held it in 5 quarters. The position peaked at $460K in Q3 2025. 203 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • AlphaQuest reported no remaining ARS Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 32,970 ARS Pharmaceuticals shares in Q1 2026, an estimated $384K.
  • AlphaQuest first reported a position in ARS Pharmaceuticals in Q4 2024 and held it in 5 quarters.
  • AlphaQuest's ARS Pharmaceuticals position peaked at $460K in Q3 2025.
  • 203 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.